
Loading, please wait...

Loading, please wait...

Recent research highlights the transformative potential of DMT psychedelic therapy in addressing substance use disorders. Conventional treatments for addiction often struggle with limited efficacy. However, a new systematic review suggests that N, N-dimethyltryptamine (DMT) could offer a significant breakthrough for patients who fail to respond to standard care.
DMT works primarily by agonising serotonin 2A (5-HT2A) receptors in the prefrontal cortex. This interaction disrupts rigid neural patterns associated with addictive behaviors. Moreover, researchers believe that the substance enhances neuroplasticity through Sigma-1 and trace amine-associated receptors. Consequently, patients often experience "ego dissolution," which facilitates deep psychological insights during the treatment process.
A comprehensive meta-analysis of studies from 1960 to 2024 evaluated the impact of DMT on substance misuse. The results showed a large overall effect size for reducing substance use. Specifically, the pooled Hedge’s g was 0.94. This indicates a robust clinical benefit compared to placebo or conventional controls. Furthermore, subgroup analyses revealed that outcomes were significantly better when the intervention included adjunctive psychotherapy. This synergy underscores the importance of a structured clinical environment.
The safety profile of DMT is generally favorable. Because DMT is fast-acting, the psychedelic experience is much shorter than psilocybin or LSD. This brevity may simplify clinical implementation in busy psychiatric settings. However, clinicians must monitor patients for transient increases in heart rate and blood pressure. In India, where substance misuse remains a critical public health challenge, these findings offer a promising path for future neuropsychiatric research and policy development.
DMT is unique due to its rapid onset and short duration of action. While psilocybin sessions can last six hours, a DMT experience typically concludes within 30 minutes.
Yes, evidence suggests that combining DMT with psychotherapy significantly enhances the reduction of substance misuse compared to the drug alone.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A 2024 systematic review and meta-analysis demonstrate that DMT psychedelic therapy significantly reduces substance misuse, especially when paired with psyc...
6 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today